Zymeworks Inc

ZYME

Healthcare|Biotechnology|USA

$25.88

-1.19 (-4.40%)

Tangible Book

$2.04

Upcoming Data Readouts (4)

Dec 2026

Est. completion

P1Advanced Solid Tumors

A Study of ZW191 in Participants With Solid Tumors

Jun 2027

Est. completion

P3Biliary Tract Neoplasms

Personalized Medicine for Advanced Biliary Cancer Patients

Sep 2027

Est. completion

P1Hepatocellular Carcinoma

A Study of ZW251 in Participants With Advanced Solid Tumors

Dec 2028

Est. completion

P2Breast Cancer

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)